search
Back to results

Blood-brain Barrier Permeability Study in Adults With Meningitis (NM-BBBP)

Primary Purpose

Blood-Brain Barrier Permeability

Status
Terminated
Phase
Not Applicable
Locations
Poland
Study Type
Interventional
Intervention
ICG-PULSION
LiMON, Pulsion Medical Systems
Gadolinium (Gadovist, Bayer, Germany)
Sponsored by
Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Blood-Brain Barrier Permeability focused on measuring Blood-Brain Barrier, Magnetic Resonance Imaging, Spectroscopy, Near-Infrared, Indocyanine green

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • patients over 18 years old
  • diagnosed with meningitis in the examination of cerebrospinal fluid

Exclusion Criteria:

  • allergic to any of the contrast agents
  • a lack of consent to the test
  • liver failure and kidney failure

Sites / Locations

  • Medical University in Bialystok

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Other

Experimental

Arm Label

ICG washout kinetics assessment

Pulse oximeter monitor

Gadolinium washout kinetics assessment

Arm Description

Intravenous administration of 5-10 mg indocyanine green (ICG-PULSION), once per subject

Monitoring of a person's oxygen saturation (SO2), peripheral oxygen saturation

20 mL of gadolinium (Gadovist, Bayer, Germany) injection at 5 mL/s, once per subject

Outcomes

Primary Outcome Measures

Correlation between blood brain barrier permeability assessment with use of near infrared spectroscopy and magnetic resonance imaging
The kinetics of the indocyanine green (ICG) outflow from the brain with the use of near-infrared spectroscopy will be a subject of investigation. ICG washout rate parameter R [a.u.] will be calculated which describes the effectiveness of the washout of ICG from the brain. It is calculated by measuring the accumulation of ICG contrast agent in the extravascular-extracellular space. The volume transfer constant (Ktrans) which reflects the efflux rate of gadolinium contrast from blood plasma into the tissue extravascular-extracellular space will be assessed during contrast-enhanced magnetic resonance imaging study. Ktrans is a measure of capillary permeability. Both parameters may reflect blood brain barrier (BBB) permeability and indicate BBB disruption. The primary outcome of the study will be correlation coefficient r [a.u.] between R and Ktrans calculated for the set of subjects. Adverse events as a consequence of ICG and/or gadolinium administration will be monitored and reported.

Secondary Outcome Measures

Full Information

First Posted
August 23, 2016
Last Updated
October 17, 2018
Sponsor
Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT02902588
Brief Title
Blood-brain Barrier Permeability Study in Adults With Meningitis
Acronym
NM-BBBP
Official Title
The Use of Near Infrared Spectroscopy and Magnetic Resonance Imaging Technique in the Evaluation of the Permeability of Blood-brain Barrier in Adults With Meningitis
Study Type
Interventional

2. Study Status

Record Verification Date
October 2018
Overall Recruitment Status
Terminated
Why Stopped
The tests have been completed
Study Start Date
August 1, 2015 (Actual)
Primary Completion Date
January 31, 2018 (Actual)
Study Completion Date
January 31, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to confirm the applicability and usefulness of the novel method of assessment of the permeability of the blood-brain barrier and in monitoring of the treatment of patients with meningitis. The proposed technique is based on evaluation of the kinetics of the indocyanine green (ICG) outflow from the brain with the use of near-infrared spectroscopy (NIRS). Usefulness of the NIRS-based method will be analyzed in relation to the reference method, which is contrast-enhanced magnetic resonance imaging (MRI).
Detailed Description
Clinical trials in healthy volunteers and in patients with diagnosed blood-brain barrier disruption: Performing a lumbar puncture as a routine diagnostic procedure in a patient with suspected neuroinfection. Biochemical assessment of the degree of the blood-brain barrier disruption based on the albumin ratio. Enrollment of patients diagnosed with neuroinfection to the study and obtaining informed consent. Performing the measurement involving fixation of the NIRS probes on the patient's head while intravenously injecting optical contrast agent - ICG (5-10 mg in a bolus). The measurement time is about 15 min. Monitoring of the patient's condition during the examination using a pulse oximeter monitor. The examination should be performed no later than 12 hours after the lumbar puncture to obtain a reliable correlation of results between the methods. The party responsible for the technical aspect of the investigation will be the Sponsor while the party responsible for the medical aspect (including the injection of the contrast agent) will be the Principal Investigator. Conducting a magnetic resonance test. The MRI imaging can be carried out before or after the test by the optical method, but with only a slight time delay (not more than 24h). The gadolinium will be injected at 5 mL/s (20 mL per patient). Calculating the cerebral blood flow and the cerebrovascular permeability coefficient and passing the information to the patient's doctor. 3. The assessment of the contrast agent outflow kinetics parameters obtained with use of the optical method 4. The correlation of the results of the of the evaluation of the blood-brain barrier condition by MRI, biochemical assessment of the cerebro-spinal fluid and optical method.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Blood-Brain Barrier Permeability
Keywords
Blood-Brain Barrier, Magnetic Resonance Imaging, Spectroscopy, Near-Infrared, Indocyanine green

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ICG washout kinetics assessment
Arm Type
Experimental
Arm Description
Intravenous administration of 5-10 mg indocyanine green (ICG-PULSION), once per subject
Arm Title
Pulse oximeter monitor
Arm Type
Other
Arm Description
Monitoring of a person's oxygen saturation (SO2), peripheral oxygen saturation
Arm Title
Gadolinium washout kinetics assessment
Arm Type
Experimental
Arm Description
20 mL of gadolinium (Gadovist, Bayer, Germany) injection at 5 mL/s, once per subject
Intervention Type
Other
Intervention Name(s)
ICG-PULSION
Intervention Description
Intravenous administration of indocyanine green
Intervention Type
Device
Intervention Name(s)
LiMON, Pulsion Medical Systems
Intervention Description
Application of near infrared light
Intervention Type
Other
Intervention Name(s)
Gadolinium (Gadovist, Bayer, Germany)
Intervention Description
Injection of gadolinium
Primary Outcome Measure Information:
Title
Correlation between blood brain barrier permeability assessment with use of near infrared spectroscopy and magnetic resonance imaging
Description
The kinetics of the indocyanine green (ICG) outflow from the brain with the use of near-infrared spectroscopy will be a subject of investigation. ICG washout rate parameter R [a.u.] will be calculated which describes the effectiveness of the washout of ICG from the brain. It is calculated by measuring the accumulation of ICG contrast agent in the extravascular-extracellular space. The volume transfer constant (Ktrans) which reflects the efflux rate of gadolinium contrast from blood plasma into the tissue extravascular-extracellular space will be assessed during contrast-enhanced magnetic resonance imaging study. Ktrans is a measure of capillary permeability. Both parameters may reflect blood brain barrier (BBB) permeability and indicate BBB disruption. The primary outcome of the study will be correlation coefficient r [a.u.] between R and Ktrans calculated for the set of subjects. Adverse events as a consequence of ICG and/or gadolinium administration will be monitored and reported.
Time Frame
up to 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: patients over 18 years old diagnosed with meningitis in the examination of cerebrospinal fluid Exclusion Criteria: allergic to any of the contrast agents a lack of consent to the test liver failure and kidney failure
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Adam Liebert, Prof.
Organizational Affiliation
Nalecz Institute of Biocybernetics and Biomedical Engineering Polish Academy of Science
Official's Role
Study Chair
Facility Information:
Facility Name
Medical University in Bialystok
City
Bialystok
ZIP/Postal Code
15-089
Country
Poland

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
21964696
Citation
Ergin A, Wang M, Zhang JY, Bruce JN, Fine RL, Bigio IJ, Joshi S. The feasibility of real-time in vivo optical detection of blood-brain barrier disruption with indocyanine green. J Neurooncol. 2012 Feb;106(3):551-60. doi: 10.1007/s11060-011-0711-5. Epub 2011 Oct 1.
Results Reference
result
PubMed Identifier
24110368
Citation
Liebert A, Milej D, Weigl W, Gerega A, Kacprzak M, Maniewski R. Fluorescence-based method for assessment of blood-brain barrier disruption. Annu Int Conf IEEE Eng Med Biol Soc. 2013;2013:3040-2. doi: 10.1109/EMBC.2013.6610181.
Results Reference
result

Learn more about this trial

Blood-brain Barrier Permeability Study in Adults With Meningitis

We'll reach out to this number within 24 hrs